All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
PERTH, Australia – Melbourne-based biotech Starpharma Ltd. expects to file its rolling NDA with the FDA in the next month following positive phase III results for Vivagel BV for preventing recurrent bacterial vaginosis.